CJC1295 DAC — Technical Research Profile

Molecular and structural context

CJC-1295 DAC is a stabilized GHRH-family analogue incorporating amino-acid substitutions and a reactive drug-affinity-complex group. The DAC moiety is designed to form a covalent linkage with circulating albumin, extending exposure in pharmacokinetic models.

Mechanistic research framework

The peptide portion activates the class B GPCR GHRHR, primarily increasing Gs-dependent cAMP and PKA signalling. The DAC modification changes disposition and apparent duration rather than creating a different receptor target.

Laboratory applications include GHRH-receptor activation, release kinetics, protein-binding behavior, and duration-of-signal comparisons.

Experimental applications and endpoint selection

Research can compare cAMP potency, albumin conjugation, free-versus-bound fraction, receptor activation over time, and endocrine-response kinetics against non-DAC analogues. Albumin concentration and incubation history should be controlled.

This material is intended for analytical, biochemical, receptor-pharmacology, cellular, or other controlled preclinical workflows as appropriate to the target system. Study design should define the biological matrix, exposure duration, concentration range, replicate structure, acceptance criteria, and statistical plan before data collection.

Principal areas of scientific inquiry

• GHRH-receptor signalling
• Extended-exposure and release kinetics
• Protein-binding and peptide-stability studies

Technical keywords

• GHRHR agonism
• Drug affinity complex
• Albumin conjugation
• Extended-exposure models

Analytical characterization considerations

Testing may need to distinguish unconjugated peptide, hydrolyzed linker species, and albumin adducts. LC-MS, RP-HPLC, protein-binding assays, and GHRHR functional assays address different aspects of identity and activity.

Where scientifically appropriate, laboratories may use orthogonal methods such as reversed-phase HPLC for chromatographic purity, LC-MS for molecular identity, size-sensitive methods for aggregation, and a target-relevant functional assay for biological activity. Method suitability, reference standards, system suitability, and acceptance limits must be independently established; these examples are not batch-specific analytical claims.

Study design and interpretation

Use vehicle, positive, negative, and concentration-matched controls appropriate to the assay. Receptor expression, biological matrix, incubation time, adsorption, proteolysis, passage number, and species background can all change apparent potency or pathway output. Observations from in vitro or animal models should not be extrapolated to human use.

Handling and documentation

Use calibrated equipment and documented receipt, storage, preparation, aliquoting, freeze-thaw, and disposal procedures. Solvent compatibility, working concentration, stability window, container adsorption, and assay recovery must be established by the purchasing laboratory using the applicable batch documentation and institutional standard operating procedures.

Important compliance and safety remarks

• No therapeutic, diagnostic, cosmetic, or veterinary claims are made.
• Work must be performed by qualified personnel under applicable institutional and regulatory requirements.
• Use appropriate personal protective equipment and controlled laboratory procedures.

For research use only. Not for human or animal consumption.